Vaporox, a Denver based medical device company, has received clearance from the US Food and Drug Administration for its next generation VHT-200 medical device system for healing chronic wounds, which are wounds that do not respond to conventional wound treatment, meeting a significant unmet medical need for millions of sufferers of diabetic foot ulcers.

In our new BioScience Colorado Magazine, CBSA highlights how companies have raised critical capital. Colorado’s angel community, including Rockies Venture Club, played an integral role in Vaporox Inc.‘s fundraising efforts. After taking the CEO role and forging a commercialization strategy that capitalized on the company’s remarkable clinical results, Alan Sage found major success in the angel market.